Reading view
Rethinking Lung Cancer Screening: AI Nodule Detection and Diagnosis Outperforms Radiologists, Leading Models, and Standards Beyond Size and Growth
MedCondDiff: Lightweight, Robust, Semantically Guided Diffusion for Medical Image Segmentation
SelfAI: Building a Self-Training AI System with LLM Agents
CACARA: Cross-Modal Alignment Leveraging a Text-Centric Approach for Cost-Effective Multimodal and Multilingual Learning
Wikontic: Constructing Wikidata-Aligned, Ontology-Aware Knowledge Graphs with Large Language Models
Multi-Modal AI for Remote Patient Monitoring in Cancer Care
A TinyML Reinforcement Learning Approach for Energy-Efficient Light Control in Low-Cost Greenhouse Systems
Human Decision-making is Susceptible to AI-driven Manipulation
The Unified Cognitive Consciousness Theory for Language Models: Anchoring Semantics, Thresholds of Activation, and Emergent Reasoning
Life-Code: Central Dogma Modeling with Multi-Omics Sequence Unification
The AI Productivity Index (APEX)
An Interdisciplinary and Cross-Task Review on Missing Data Imputation
Maximizing the efficiency of human feedback in AI alignment: a comparative analysis
Exosome-Mediated RUNX3 DNA Delivery for Lung Cancer Therapy
ACS Appl Mater Interfaces. 2025 Dec 1. doi: 10.1021/acsami.5c15987. Online ahead of print.
ABSTRACT
Gene therapy represents a promising strategy for treating lung cancer, with the potential to inhibit the proliferation of cancerous cells and induce apoptosis. However, current gene therapy for lung cancer encounters challenges with delivery, targeting, and safety, such as off-target effects, immune responses, and the necessity for better delivery methods. Here, we introduce gene therapy using the key regulator in lung adenocarcinoma, runt-related transcription factor 3 (RUNX3), within exosomes (Exos), which are known for their biocompatibility and ability to selectively target cancer cells. We packaged the RUNX3 plasmid DNA into human exosomes (hExo-Rs), designed to target and induce apoptosis in cancer cells, resulting in a viability decrease to 43.3%. Normal fibroblasts remained viable at 96.0%, confirming the safety of hExo-Rs for future therapies. We delivered hExo-Rs to cancer spheroids, examined their effects, and found that cytokines from treated cells promote M1 macrophage polarization, emphasizing their potential for immunotherapy. We developed a hydrogel platform for the targeted 14-day release of RUNX3 pDNA by attaching hExo-Rs to gelatin using microbial transglutaminase, which enables the selective decrease in cancer cell viability and confirms apoptosis. Our demonstration of RUNX3 gene therapy with Exos presents selective anticancer effectiveness and the promise of clinical use through localized, sustained release using the hydrogel.
PMID:41325015 | DOI:10.1021/acsami.5c15987
STAT+: A drug that was ‘engineered with AI’ enters Phase 3 testing
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. My colleagues will be in Orlando later this week for the American Society of Hematology meeting. Sign up for their newsletter to stay on top of the news from the conference. We’re also holding an event there on Friday.
Fight around hospital drug discount program escalates with new lawsuit
The American Hospital Association and several hospital systems have filed a lawsuit against the Trump administration, seeking to halt an upcoming pilot program for a controversial drug discount program.
Continue to STAT+ to read the full story…


© Adobe
Opinion: Racial bias in medicine can be as simple as dismissing Black patients as a ‘hard stick’
I was moments away from a routine screening colonoscopy when it happened again. The warm and professional pre-procedure nurse began preparing for intravenous insertion. She tied the tourniquet loosely around my arm, took a quick glance, and untied it within seconds. “I can’t find a vein. You must be dehydrated,” she said, moving immediately to the back of my hand.
I paused. I didn’t feel dehydrated. Yes, I had followed the bowel prep instructions, consuming only liquids the day before, but I had no signs of dehydration. I knew my body. I knew my veins.


© AIZAR RALDES/AFP via Getty Images
The role of digital twins in P4 medicine: A paradigm for modern healthcare
npj Digital Medicine, Published online: 01 December 2025; doi:10.1038/s41746-025-02115-x
The role of digital twins in P4 medicine: A paradigm for modern healthcare